We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Quantization of Leukocyte Subsets with DNA Methylation Microarrays

By LabMedica International staff writers
Posted on 20 Mar 2014
A novel microarray-based technique uses DNA methylation to simultaneously quantify multiple leukocyte subsets, enabling the investigation of immune modulations in both fresh blood samples and archived samples that previously could not be used for such analysis.

Cell lineage-specific DNA methylation patterns distinguish normal human leukocyte subsets and can be used to detect and quantify these subsets in peripheral blood. More...
However, all the current methods for counting immune cells in a blood sample require whole cells, with the "gold standard" methods being: manual five-part differential count, CBC (complete blood count) with automated five-part differential and fluorescence-activated cell sorting (FACS).

Investigators at Brown University (Providence, Rhode Island, USA) have developed an approach using DNA methylation to simultaneously quantify multiple leukocyte subsets without the need for counting whole cells.

They used the Illumina (San Diego, CA, USA) Infinium HumanMethylation and VeraCode GoldenGate Methylation microarray assays to identify cell lineage-specific DNA methylation signatures that distinguished among human T-cells, B-cells, NK cells, monocytes, eosinophils, basophils and neutrophils. They then employed a bioinformatics-based approach to quantify these cell types in complex mixtures, including whole blood, using DNA methylation signatures at as few as 20 CpG (cytosine and the guanine connected by a phosphodiester bond) loci.

Applying this DNA methylation-based approach to quantify the cellular components in 80 human whole blood samples, they verified its accuracy by direct comparison to gold standard immune quantification methods that utilized physical, optical, and proteomic characteristics of the cells. They also demonstrated that the approach was not affected by storage of blood samples, even under conditions prohibiting the use of gold standard methods.

“Every kind of cell has its own methylation signature,” said senior author Dr. Karl T. Kelsey, professor of epidemiology at Brown University. “Once you understand the unique and really immutable signature that directs the differentiation of the cell, then you can use that and you do not need the cell anymore.”

The study was published in the March 5, 2014, online edition of the journal Genome Biology.

Related Links:

Brown University
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Pipette Calibration System
Artel PCS®
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.